Clinical Trial Spotlight: Should a Second Generation ALK Inhibitor be First Line Therapy for Patients with ALK-Positive NSCLC?
14 de nov. de 2015 ·
4m 13s
Regístrate gratis
Escucha este episodio y muchos más. ¡Disfruta de los mejores podcasts en Spreaker!
Descarga y escucha en cualquier lugar
Descarga tus episodios favoritos y disfrútalos, ¡dondequiera que estés! Regístrate o inicia sesión ahora para acceder a la escucha sin conexión.
Descripción
Dr. Jack West asks the question of whether newer, more active ALK inhibitors such as alectinib should be used as first line therapy rather than for acquired resistance, including introducing...
mostra más
Dr. Jack West asks the question of whether newer, more active ALK inhibitors such as alectinib should be used as first line therapy rather than for acquired resistance, including introducing the ALEX trial that is trying to answer this question.
mostra menos
Información
| Autor | cancerGRACE |
| Página web | - |
| Etiquetas |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
